quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 12, 2026

Oracle Corporation (ORCL) Investors: Kessler Topaz Meltzer & Check, LLP Announces that the Firm has Filed a Securities Fraud Class Action Lawsuit Against Oracle Corporation and Encourages Investors to Contact the Firm

View original at globenewswire.com
Oracle Corporation (ORCL) Investors: Kessler Topaz Meltzer & Check, LLP Announces that the Firm has Filed a Securities Fraud Class Action Lawsuit Against Oracle Corporation and Encourages Investors to Contact the Firm RADNOR, Pa., Feb…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Oracle's future lease exposure far exceeds similar commitments by peers, with a mismatch between the long duration of the property leases and much shorter contracts with key customers such as OpenAI

    80% confidence
  • Oracle has very good line-of-sight for capabilities to spend on CapEx right before it starts generating revenue

    80% confidence
  • Oracle pushed back completion dates for data centers developing for OpenAI to 2028 from 2027 due to labor and material shortages

    80% confidence
  • OpenAI could account for more than a third of total Oracle revenues by fiscal 2028 and even a greater share by fiscal 2030

    80% confidence
  • Oracle really matters because it is the harbinger of the AI capex boom, and this repricing in debt markets is very consistent with the view that risks are building

    80% confidence
  • Blue Owl Capital pulled out of funding a $10 billion Oracle data center intended to serve OpenAI as a result of concerns about Oracle's spending commitments and rising debt levels

    80% confidence
  • Oracle's promises of massive new revenues from its increased AI infrastructure business were unlikely to materialize

    80% confidence
  • Oracle's AI infrastructure strategy would result in massive increases in CapEx without equivalent, near-term growth in revenue; the Company's substantially increased spending created serious risks involving Oracle's debt and credit rating, free cash flow, and ability to fund its projects

    80% confidence
  • Oracle stock price target of $175, representing a 40% pullback

    80% confidence
  • OpenAI's ability to meet contractual obligations will be contingent on AI tailwinds continuing and its models being a market leader to continue to raise external financing

    80% confidence
  • Oracle expects to spend less than $100 billion on AI growth plans

    80% confidence
  • Oracle's $248 billion lease commitment disclosure is a bombshell disclosure, with lease commitments increasing massively from just under $100 billion in the prior quarter

    80% confidence
  • The Company's substantially increased spending on AI infrastructure would rapidly convert into accelerating revenue and profit growth

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Oracle Corporation (ORCL) Investors: Kessler Topaz Meltzer & Check, LLP Announces that the Firm has Filed a Securities Fraud Class Action Lawsuit Against Oracle Corporation and Encourages Investors to Contact the Firm — Source | Via News | pt.VIA.NEWS